Literature DB >> 33930474

Current knowledge and management of portal vein thrombosis in cirrhosis.

Marco Senzolo1, Guadalupe Garcia-Tsao2, Juan Carlos García-Pagán3.   

Abstract

Portal vein thrombosis (PVT) is an increasingly recognised complication of cirrhosis whose incidence increases in parallel with the severity of cirrhosis. Several risk factors have been associated with the occurrence and progression of PVT. Although the negative effect of complete PVT on the surgical outcome of liver transplant recipients is clear, its impact on cirrhosis progression remains uncertain. Treatment options include anticoagulants and interventional thrombolytic therapies, which are chosen almost on a case-by-case basis depending on the characteristics of the patient and the thrombus. In this manuscript, we review current knowledge regarding the epidemiology, risk factors, diagnosis and classification, natural history, clinical consequences and treatment of non-neoplastic PVT in cirrhosis.
Copyright © 2021. Published by Elsevier B.V.

Entities:  

Keywords:  Cirrhosis; Coagulopathy; Portal hypertension; Portal vein thrombosis; TIPS; Transplant

Mesh:

Year:  2021        PMID: 33930474     DOI: 10.1016/j.jhep.2021.04.029

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  9 in total

1.  Rebalanced hemostasis in liver disease: a misunderstood coagulopathy.

Authors:  Lara N Roberts
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2021-12-10

2.  A network meta-analysis of direct oral anticoagulants for portal vein thrombosis in cirrhosis.

Authors:  Cheng Han Ng; Darren Jun Hao Tan; Kameswara Rishi Yeshayahu Nistala; Nicholas Syn; Jieling Xiao; Eunice Xiang Xuan Tan; Felicia Zuying Woo; Nicholas W S Chew; Daniel Q Huang; Yock Young Dan; Arun J Sanyal; Mark D Muthiah
Journal:  Hepatol Int       Date:  2021-08-21       Impact factor: 9.029

3.  More Pronounced Hypercoagulable State and Hypofibrinolysis in Patients With Cirrhosis With Versus Without HCC.

Authors:  Marco Senzolo; Paolo Simioni; Alberto Zanetto; Elena Campello; Cristiana Bulato; Sabrina Gavasso; Graziella Saggiorato; Sarah Shalaby; Luca Spiezia; Umberto Cillo; Fabio Farinati; Francesco Paolo Russo; Patrizia Burra
Journal:  Hepatol Commun       Date:  2021-08-16

4.  Neutrophil extracellular traps are associated with enhanced procoagulant activity in liver cirrhosis patients with portal vein thrombosis.

Authors:  Yueyi Xing; Yueping Jiang; Shichao Xing; Tao Mao; Ge Guan; Qinghui Niu; Xianzhi Zhao; Jianrui Zhou; Xue Jing
Journal:  J Clin Lab Anal       Date:  2022-04-18       Impact factor: 3.124

5.  A Dynamic Nomogram Predicting Portal Vein Thrombosis in Cirrhotic Patients During Primary Prophylaxis for Variceal Hemorrhage.

Authors:  Shuo Zhang; Bing Ji; Xuan Zhong; Lan Zhong; Li Yang; Changqing Yang
Journal:  Front Med (Lausanne)       Date:  2022-06-03

6.  Chronic Portal Vein Thrombosis with Percutaneous Main Portal Vein Reconstruction and Coil Embolization of a Massive Coronary Vein: A Case Report.

Authors:  Stephanie Assimonye; Steve Lemons; Adam Alli
Journal:  Am J Case Rep       Date:  2022-08-25

7.  Risk factors for portal vein thrombosis or venous thromboembolism in a large cohort of hospitalized cirrhotic patients.

Authors:  Maria Assunta Zocco; Francesca Romana Ponziani; Mariella Faccia; Francesco Santopaolo; Antonio Gasbarrini; Maurizio Pompili
Journal:  Intern Emerg Med       Date:  2022-01-25       Impact factor: 5.472

8.  Platelet-derived TGF-β1 is related to portal vein thrombosis in cirrhosis by promoting hypercoagulability and endothelial dysfunction.

Authors:  Siyu Jiang; Yingjie Ai; Liyuan Ni; Ling Wu; Xiaoquan Huang; Shiyao Chen
Journal:  Front Cardiovasc Med       Date:  2022-09-26

9.  A practical nomogram based on systemic inflammatory markers for predicting portal vein thrombosis in patients with liver cirrhosis.

Authors:  Yueyi Xing; Zibin Tian; Yueping Jiang; Ge Guan; Qinghui Niu; Xueguo Sun; Rongshuang Han; Xue Jing
Journal:  Ann Med       Date:  2022-12       Impact factor: 4.709

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.